Breast Cancer Drug Trastuzumab (Herceptin) Shows Unprecedented Survival In Aggressive
Data from the ToGA study presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida showed that adding trastuzumab to standard chemotherapy (capecitabine [Xeloda®] or intravenous 5-FU and cisplatin) prolongs the lives of patients with this aggressive cancer on average by nearly 2.7 months to 13.8 months, a 26% increase in survival.
More... |
All times are GMT -7. The time now is 08:52 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021